High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia:biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies

Prognostic impact of peripheral blood white blood cell count (WBC) at the diagnosis of childhood acute lymphoblastic leukaemia (ALL) was evaluated in a population-based consecutive series of 2666 children aged 1-15 treated for ALL between 1992 and 2008 in the five Nordic countries (Denmark, Finland,...

Full description

Bibliographic Details
Published in:European Journal of Haematology
Main Authors: Vaitkeviciene, Goda, Forestier, Erik, Hellebostad, Marit, Heyman, Mats, Jonsson, Olafur G, Lähteenmäki, Päivi M, Rosthoej, Susanne, Söderhäll, Stefan, Schmiegelow, Kjeld, Vaitkevičienė, Goda
Format: Article in Journal/Newspaper
Language:English
Published: 2011
Subjects:
Norway
Iceland
Online Access:https://curis.ku.dk/portal/da/publications/high-white-blood-cell-count-at-diagnosis-of-childhood-acute-lymphoblastic-leukaemia(de8a43ab-ecc4-4805-80e3-53ddc2ad12d3).html
https://doi.org/10.1111/j.1600-0609.2010.01522.x
Description
Summary:Prognostic impact of peripheral blood white blood cell count (WBC) at the diagnosis of childhood acute lymphoblastic leukaemia (ALL) was evaluated in a population-based consecutive series of 2666 children aged 1-15 treated for ALL between 1992 and 2008 in the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). Ten-year event-free (pEFS(10 y)) survival and overall (pOS(10 y)) survival were 0.75 ± 0.01 and 0.85 ± 0.01, respectively. Although treatment intensity was determined by WBC, non-remission and relapsed patients still had significantly higher WBC than those in remission for B-cell precursor (BCP) (median WBC: 24.8 vs. 14.0 vs. 8.3 × 10(9) /L, P <0.001), but not for T-lineage (T-ALL) (median WBC: 127.8 vs. 113.0 vs. 86.8 × 10(9) /L, P = 0.22). pEFS was inversely related to WBC for BCP (P <0.001), but not for T-ALL. WBC was not associated with risk of event for BCP or T-ALL for patients with minimal residual disease at the end of induction (MRD(d29) )

Similar Items